CytRx Corporation Reports 2018 Financial Results

Author's Avatar
Mar 29, 2019
Article's Main Image

LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with Immunotherapy

Out-licensed Assets Aldoxorubicin and Arimoclomol with Strategic Partners

PR Newswire